Bavarian Nordic catches up to rival Valneva with broad chikungunya vaccine approval from FDA
Valneva may have won the chikungunya vaccine race with its world-first approval, but Bavarian Nordic's option is the first to offer virus protection to adolescents 12 and older.
Valneva may have won the chikungunya vaccine race with its world-first approval, but Bavarian Nordic's option is the first to offer virus protection to adolescents 12 and older.
